Trial Profile
A pilot study of low dose capecitabine plus trastuzumab as first line treatment for patients with HER2-positive advanced gastric cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 10 Dec 2015 New trial record